Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NIH Funding Boosts New Alzheimer’s Research

Published: Wednesday, September 18, 2013
Last Updated: Wednesday, September 18, 2013
Bookmark and Share
$45 million has been awarded to test early interventions and explore new approaches.

Researchers will test promising drugs aimed at preventing Alzheimer’s and identify and validate biological targets for novel therapies, with approximately $45 million in new funding from the National Institutes of Health. The initiative will support innovative new studies as part of an intensified national effort to find effective interventions for this devastating degenerative brain disease. 

The studies are among the first to be developed with direction from the 2012 NIH Alzheimer’s Disease Research Summit: Path to Treatment and Prevention and reflect research goals in the National Plan to Address Alzheimer’s Disease. Of the funding, $40 million is from an allocation from the Office of the NIH Director, Dr. Francis Collins, with additional funding from the National Institute on Aging (NIA), the lead Institute within NIH for Alzheimer’s research. 

“As many as 5 million Americans face the challenge of Alzheimer’s disease, which robs them of their memories, their independence, and ultimately, their lives,” Dr. Collins said. “We are determined, even in a time of constrained fiscal resources, to capitalize on exciting scientific opportunities to advance understanding of Alzheimer’s biology and find effective therapies as quickly as possible.” 

The clinical trials investigate possible ways to stop the progression of the disease. The translational research study awards are focused on identifying, characterizing and validating novel therapeutic targets.

“We know that Alzheimer’s-related brain changes take place years, even decades, before symptoms appear. That really may be the optimal window for drugs that delay progression or prevent the disease altogether,” said NIA Director Dr. Richard Hodes. “The clinical trials getting under way with these funds will test treatments in symptom-free volunteers at risk for the disease, or those in the very earliest stages — where we hope we can make the biggest difference.” 

Basic and genetic studies of the disease — from the abnormal proteins involved, to genetic influences, to inflammation and other Alzheimer’s - related brain changes—have advanced our knowledge. This has given us new insights into the biological underpinnings of this extremely complex disorder, Dr. Hodes said. 

Today’s awards support the following clinical trials. (Individual investigators can be contacted about when these studies will recruit participants.):

The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Trial — Dr. Randall Bateman, Washington University, St. Louis, and co-investigators. $1.5 million in fiscal 2013, with the potential for $6 million over four years

The trial is testing new anti-amyloid-beta drug treatments in volunteers who have an inherited form of Alzheimer’s disease. While early-onset Alzheimer’s is rare, the knowledge gained from this study will be highly relevant to both early-and late-onset forms of the disease. This rare form can occur in people as early as their 30s. Amyloid plaques in the brain are a hallmark of Alzheimer’s and are thought to interfere with communication among brain cells, and anti-amyloid-beta therapies attempt to treat that process. Dr. Bateman will lead a team recruiting volunteers free of symptoms or in the earliest stages of the disorder.

The four-year trial, a multi-site international effort, will test three anti-amyloid-beta interventions: gantenerumab, solanezumab and a third, as yet undetermined, drug. This trial is also supported by the Alzheimer's Association® and the following companies: Roche, Lilly, Avid Radiopharmaceuticals and CogState. (NIA support: AG042791-01A1)

The Alzheimer's Prevention Initiative APOE4 Trial — Drs. Eric Reiman and Pierre Tariot, Banner Alzheimer’s Institute, Phoenix, and co-investigators. Fully funded in fiscal 2013 at $33.2 million 

This five-year prevention trial proposes to test an anti-amyloid drug in cognitively normal older volunteers who are at increased risk of developing late-onset Alzheimer’s because they inherited two copies of the APOE4 allele, the best known genetic risk for late-onset disease. The treatment, which has not yet been selected, will be tested in this randomized, controlled clinical trial at multiple sites. Participants will be assessed through cognitive tests, brain imaging and cerebrospinal fluid measurements to evaluate whether the drug impacts amyloid, other biological measurements and the memory and thinking problems related to the disease. The study will test the role of amyloid in the development of Alzheimer’s and will, through imaging and biomarker techniques, help identify faster ways to evaluate other promising prevention therapies in the future. It is anticipated that the study will also be supported with private funding. (NIA support: AG 046150-01)

Allopregnanolone Regenerative Therapeutic for MCI/Alzheimer’s: Dose Finding Phase 1 — Drs. Roberta Brinton and Lon Schneider, University of Southern California, Los Angeles. Fully funded in fiscal 2013 at $2.4 million

This early-phase clinical trial will evaluate over 12 weeks the safety and tolerability of increasing doses of allopregnanolone, a natural brain steroid, in treating mild cognitive impairment and Alzheimer’s disease. The drug has been shown to promote the generation of new brain cells, reduce amyloid levels, and restore cognitive function in pre-clinical animal testing. NIA has supported Dr. Brinton’s research over many years, including basic science grants to understand allopregnanolone’s mechanism of action in the brain, a drug development grant which included development of optimal dose and formulation, and support for pre-clinical toxicology studies. This support helped bring Dr. Brinton and colleagues to the stage of being able to go into a human Phase I trial. (NIA support: AG 046148-01) Studies focused on the identification and validation of novel therapeutic targets for Alzheimer’s disease include: 

Pathway Discovery, Validation and Compound Identification for Alzheimer’s Disease — Drs. Philip De Jager, of the Brigham and Women's Hospital, Broad Institute, Harvard University, Boston, and David Bennett, of Rush University Medical Center, Chicago. $1.7 million in fiscal 2013, with the potential of $7.9 million over five years

The study will discover, characterize and validate complex molecular networks and candidate genes that influence susceptibility to cognitive decline and Alzheimer’s disease. Using cutting-edge computational methods, this multi-disciplinary team will analyze rich clinical, pathological, genomic and other large-scale molecular data collected from over 1,000 volunteers from the Religious Order Study and the Rush Memory and Aging Project. 

Through a systems biology approach looking at biological interactions involved in the disease, the project ultimately seeks to identify compounds that normalize the activity of dysfunctional nodes in molecular networks and to identify drugs for several novel therapeutic targets. To accelerate the testing of promising therapies for future clinical trials, the researchers will focus on drugs that have already undergone Phase I testing in humans. (NIA support: AG 046152)

Integrative Biology Approach to Complexity of Alzheimer’s Disease — Dr. Eric Schadt of Icahn School of Medicine at Mount Sinai, New York City, and a team of investigators. $1.6 million in fiscal 2013, with the potential of $8.2 million over five years

This study will apply innovative analytical methods to large-scale molecular, cellular and clinical data from Alzheimer’s patients to construct biological network models and gain new insights into the complex mechanisms of the disease. Several cellular and animal models will be used to validate the actions of individual genes, as well as entire molecular networks predicted to drive the disease. The team will also employ a computational approach to test whether any existing drugs currently used for other conditions are capable of modulating the Alzheimer’s networks and can, therefore, be repurposed for Alzheimer’s treatment or prevention. (NIA support: AG 046170-01)

A Systems Approach to Targeting Innate Immunity in Alzheimer’s — Dr. Todd Golde, University of Florida, Gainesville, and colleagues. $1.6 million in fiscal 2013, with the potential of $7.7 million over five years

This study builds on the genetic and pathological evidence that the innate immune system, which provides immediate defense against infection, and brain inflammation have a significant role in Alzheimer’s disease. To identify and characterize novel therapeutic targets within the innate immune system, this study will use a systems biology approach to integrate genomic, gene expression, and pathological data from Alzheimer’s patients and Alzheimer’s mouse models and analyze them in novel ways. The team will test in animal models of the disease the validity and therapeutic potential of the key factors predicted by the analysis. This has the potential to speed the discovery and testing of Alzheimer’s disease prevention and treatment therapies by targeting the immune system. (NIA support: AG 046139-01).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Public Support for National Study
Survey shows the majority of respondents support or show willingness for national precision medicine study.
Thursday, August 18, 2016
How Parkinson’s Disease Alters Brain Activity Over Time
The NIH study provides a new tool for testing experimental medications aimed at alleviating symptoms and slowing the rate at which the diseases damage the brain.
Tuesday, August 16, 2016
Schizophrenia, Autism Share Genetic Causes
Monkey brain developmental atlas pinpoints when, where genes activate.
Tuesday, August 16, 2016
Depression Genetics Insight from Crowd-Sourced Data
Genome sites liked to depression have been discovered from data shared by people who had purchased their genetic profiles online.
Tuesday, August 02, 2016
NIH Funds Precision Medicine
NIH have committed roughly $31M to launch a new program for Transdisciplinary Collaborative Centers for health disparities research.
Friday, July 29, 2016
NIH Funds Million-Person Medicine Study
NIH announces $55million in awards to build foundations for ambitious Cohort Program that aims to engage 1 million participants in lifestyle, environments and genetics research.
Friday, July 08, 2016
NIH Funds Biobank To Support Precision Medicine Initiative Cohort Program
$142 million over five years will be awarded to the Mayo Clinic to establish the world’s largest research-cohort biobank for the PMI Cohort Program
Friday, May 27, 2016
Tick Genome Reveals Secrets of a Successful Bloodsucker
NIH-funded study could lead to new tick control methods.
Tuesday, February 09, 2016
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Monday, February 08, 2016
Genome-Wide Study Yields Markers of Lithium Response
An international consortium of scientists has identified a stretch of chromosome that is associated with responsiveness to the mood-stabilizing medication lithium among patients with bipolar disorder.
Monday, February 01, 2016
Schizophrenia’s Strongest Known Genetic Risk Deconstructed
Suspect gene may trigger runaway synaptic pruning during adolescence – NIH-funded study.
Thursday, January 28, 2016
NIH Genome Sequencing Program Targets the Genomic Bases of Common, Rare Disease
The National Institutes of Health will fund a set of genome sequencing and analysis centers whose research will focus on understanding the genomic bases of common and rare human diseases.
Friday, January 15, 2016
Three Glaucoma-Related Genes Discovered
NIH-funded genetics analysis of glaucoma is largest to date.
Tuesday, January 12, 2016
Biomarkers Outperform Symptoms in Parsing Psychosis Subgroups
Multiple biological pathways lead to similar symptoms - NIH-funded study.
Thursday, December 10, 2015
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
Tuesday, December 01, 2015
Scientific News
Breast Cancer Cells Found To Switch Molecular Characteristics
Spontaneous interconversion between HER2-positive and HER2-negative states could contribute to progression, treatment resistance in breast cancer.
Some Breast Cancer Patients With Low Genetic Risk Could Skip Chemotherapy
Genetic test can help predict survival and guide treatment options.
LncRNAs Maintain Immune Health
Long non-coding RNAs are key controllers for maintaining immune health when fighting infection or preventing inflammatory disorders.
Enzyme that Triggers Cell Demise in ALS Identified
Scientists from Harvard have identified a key instigator of nerve cell damage in people with amyotrophic lateral sclerosis (ALS).
Molecular Alarm Clock Wakes Resting Ovules
Study of fruit flies yields discovery of a molecular "alarm clock" that activates resting ovules.
Improved Immunity in Older Age
A study from Oxford and Basel universities may point the way to maintaining our immune systems as we get older.
Neurodvelopmental Disorder Cause Linked to SON Gene
A genetic link has been discovered for a previously unxplained neurodevelopmental disorder.
Russian TB Thrives Within Macrophages
MIPT researchers have identified features of mycobacterium tuberculosis strains that may explain their success.
Gene Linked to Hearing Loss Identified
Researchers have identifed a gene associated with age-related hearing loss.
World's Most In-Depth Study to Detect Alzheimer's Disease
A multisite team will see the most thorough and vigorous testing for Alzheimer's ever performed on volunteers.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!